02046nas a2200265   4500000000100000000000100001008004100002260000900043653002600052653002600078653003400104653001800138653001300156653001700169653003000186100001600216700003000232700002100262700002200283245009400305300001100399490000700410520134900417022001401766       2022                            d  c202210aAlzheimer’s disease10aParkinson’s disease10aamyotrophic lateral sclerosis10abrain-on-chip10ain vitro10amicrofluidic10aneurodegenerative disease1 aLouise Miny1 aBenoît G. C. Maisonneuve1 aIsabelle Quadrio1 aThibault Honegger00aModeling Neurodegenerative Diseases Using In Vitro Compartmentalized Microfluidic Devices  a9196460 v103 aThe human brain is a complex organ composed of many different types of cells interconnected to create an organized system able to efficiently process information. Dysregulation of this delicately balanced system can lead to the development of neurological disorders, such as neurodegenerative diseases (NDD). To investigate the functionality of human brain physiology and pathophysiology, the scientific community has been generated various research models, from genetically modified animals to two- and three-dimensional cell culture for several decades. These models have, however, certain limitations that impede the precise study of pathophysiological features of neurodegeneration, thus hindering therapeutical research and drug development. Compartmentalized microfluidic devices provide in vitro minimalistic environments to accurately reproduce neural circuits allowing the characterization of the human central nervous system. Brain-on-chip (BoC) is allowing our capability to improve neurodegeneration models on the molecular and cellular mechanism aspects behind the progression of these troubles. This review aims to summarize and discuss the latest advancements of microfluidic models for the investigations of common neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.  a2296-4185